Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by LannyMcdonaldon Apr 11, 2017 12:36pm
169 Views
Post# 26107465

When you start to feel shitty about the Stock price!!

When you start to feel shitty about the Stock price!!Go back and read the Technology MarketWatch Journal and remind yourself why your hear!..........How big will this get (ONLY ANDRE KNOWS)? The answer is 'we just don't know' (MAYBE THE ANALYST WILL LET US IN ON THE SECRET), but there are numerous indicators ADK.V is going on a massive run (TO THE BASEMENT UNTIL THE NEXT PR)............ DIAGNOS' test is painless (WATCHING THE STOCK PRICE IS NOT) and quick, generally taking 2 - 3 minutes maximum.......... Having artificial intelligence in the loop to take care of a very demanding interpretation task that requires a high degree of proficiency, consistency, and accuracy 24/7 is a great benefit to specialists (MAYBE WE SHOULD LET THE ARTIFICIAL INTELLIGENCE PROMOTE THE STOCK). DIAGNOS' software can operate at the same high level all day long (WHERE THE CEO CANNOT), where as traditional methods rely upon alertness of humans (ANDRE WAKE UP!). Government involvement with DIAGNOS is the big prize for shareholders; when (WHEN, WHEN, WHEN) key news is announced, we anticipate it will act as a major catalyst that will supplant all current projections and cause a dramatic upside revaluation (OR MAYBE AN UPCHUCK) in share price, well above what is being discussed here today (OR MAYBE NOT)...... Medical Software Has the Mechanics of a Great Business....... When (WHEN, WHEN,) mature (WE MAY SEE SOME REVENUE NUMBERS), DIAGNOS promises to provide investors with a steady stream of recurring (HEADACHES) revenues! While DIAGNOS has a disruptive healthcare technology that looks poised to become a robust business (LOOKS CAN BE DECEIVING), valuing the Company at such an early stage of adoption for its technology and business model is challenging, especially with the Company only this fiscal Q3 (ending December-2016) demonstrating a turn to profitability (WE WILL GIVE THEM THAT). An analysis of qualitative factors provides further support that the shares are due for significant upward revaluation (NOT BEFORE A RUN TO THE BASEMENT). In contrast to some other names in the healthcare sector, DIAGNOS' management has been more interested in running the business than promoting the stock (REALLY I DIDNT NOTICE WITH ALL THE PRs WE HAD THIS WEEK). With the Company's turn to profitability closing out 2016 and a ramp-up of patient tests on tap, more attention is headed the Company's way (RIGHT NOW NOT IN A GOOD WAY), and we expect management will dedicate more resources on responsibly relaying its story to potential investors (OR WE MAY HAVE TO PULL SOME TEETH TO GET REVENUE NUMBERS OUT OF THE CEO). ............Just a little humour to brighten up your day..........Like Dr Evil said ...... Throw us a Fricken Bone here would ya Andre!!!!
Bullboard Posts